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Background and aim: Patient decision aids for oncological treatment options, provide information on the
effect on recurrence rates and/or survival benefit, and on side-effects and/or burden of different treat-
ment options. However, often uncertainty exists around the probability estimates for recurrence/survival
and side-effects which is too relevant to be ignored. Evidence is lacking on the best way to communicate
these uncertainties. The aim of this study is to develop a method to incorporate uncertainties in a patient
decision aid for breast cancer patients to support their decision on radiotherapy.
Methods: Firstly, qualitative interviews were held with patients and health care professionals. Secondly,
in the development phase, thinking aloud sessions were organized with four patients and 12 health care
professionals, individual and group-wise.
Results: Consensus was reached on a pictograph illustrating the whole range of uncertainty for local
recurrence risks, in combination with textual explanation that a more exact personalized risk would be
given by their own physician. The pictograph consisted of 100 female icons in a 10 x 10 array. Icons with a
stepwise gradient color indicated the uncertainty margin. The prevalence and severity of possible side-
effects were explained using verbal labels.
Conclusions: We developed a novel way of visualizing uncertainties in recurrence rates in a patient
decision aid. The effect of this way of communicating risk uncertainty is currently being tested in the
BRASA study (NCT03375801).
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ealth care professionals; PtDA, patient decision aid; DCS, ductal carcinoma in situ; BCSS, breast cancer specific survival;
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In health care, the best treatment for the individual patient is a
tradeoff between the medical advantages and disadvantages of
different treatment options and the personal values and prefer-
ences of the patient. This tradeoff is most relevant in preference-
sensitive decisions: treatment decisions where no best treatment
exists [1e3].
Some breast cancer patients, e.g. with an intermediate risk local
recurrence risk (LRR), face such a preference-sensitive decision
when deciding on adjuvant radiotherapy. The benefits of radio-
therapy consist of a decrease in the risk of recurrence and some-
times a small survival benefit [4e9]. The disadvantages are possible
side-effects and treatment burden. In many cases however, the
exact recurrence risks are unknown. This is amongst other reasons
due to literature based on outdated trials; breast cancer clinical
trials having a long follow-up whilst new treatment options
develop fast. Another reason is that clinical trials use strictly defined
patient categories and patients do not always fit in the trial popu-
lation [7]. Therefore, estimated recurrence risks are surrounded by
an uncertainty margin. Some guidelines reflect this uncertainty,
advocating shared decision making with the patient [5].
There are two levels of uncertainty. First-order/aleatory uncer-
tainty, is the uncertainty of an event taking place in the future. The
risk estimate is known on group level, but it is difficult to predict
whether it will happen yes or no in the individual patient. Second-
order/epistemic uncertainty, is the uncertainty around the risk
estimates [10]. There is even uncertainty on the risk estimate on
group level. Little is known on the best way to communicate risks
and uncertainties to patients [11,12]. Risks and aleatory uncertainty
are hard to understand for patients [13]. Communicating epistemic
uncertainty is even a bigger challenge. Therefore, if clinicians
communicate risks to patients, point estimates are commonly used.
From ethical and medical-legal considerations, it can be argued
though that patients should be fully informed on their treatment
options including the uncertainty around these point estimates
[14,15].
There is also epistemic uncertainty around the prevalence and
severity of the side-effects of radiotherapy for breast cancer pa-
tients. First, the available literature mentioning prevalence and
severity of side-effects is inconsistent, partly due to the use of
different scoring systems to record side-effects [16]. Consequently,
literature gives a wide range of prevalence and severity estimates
[17,18]. Second, long-term side effects occur months to many years
after irradiation, such that not all side-effects may be captured by
registries and that by the time late side-effects occur, new treat-
ments have become the standard [19]. Third, patient and treatment
characteristics influence the risk of developing certain side-effects,
making it harder to translate general risk estimates to specific es-
timates for individual patients [20].
A patient decision aid (PtDA) may be used to support the deci-
sion process and communication of risks and uncertainty [21].
PtDAs are tools that provide evidence based information on the
advantages and disadvantages of different treatment options, make
clear that they can decide between these options, and help patients
to clarify which attributes are most important to them when
making a medical decision [21]. However, there is no clear guide-
line on how uncertainty should be communicated in a PtDA.
Therefore, there is large heterogeneity in how this is done [22]. In a
review by Bansback et al. [23] only half of the tools described
epistemic uncertainty. If epistemic uncertainty was mentioned it
was mostly referred to in a qualitative way (large, small etc.).
Although it might seem that these qualitative labels are better-
understood compared to quantitative risks [24], it is known that
patients interpret qualitative labels in very different ways. Forexample Freeman describes that the term “common” in an infor-
mation leaflet is used for a side-effect occurring in 1e10% of cases,
while doctors interpret common as something occurring in 25% of
cases and patients in 50% of cases [15].
Although several PtDAs have been developed for early stage
breast cancer patients, deciding on different treatment options, to
our knowledge there are only two PtDAs for breast cancer patients
deciding on radiotherapy [25]. Both have been developed in Canada
for patients deciding on radiotherapy after lumpectomy and do not
include information on uncertainty around the point estimates or
side-effects [26,27]. Therefore, the primary objective of this study
was first to assess opinions and attitudes of breast cancer patients
and professionals on if, and how, to communicate uncertainties in
recurrence rates, survival, and side-effects. The second objective
was to incorporate this knowledge in a PtDA for breast cancer pa-
tients to support their decision on radiotherapy.
2. Methods
For the content of the PtDA we followed the guidelines of the
International Patient Decision Aid Standards (IPDAS) [28,29]. From
the start, it was clear that the PtDA had to bemade for four different
pathways:
1) Patients with low risk ductal carcinoma in situ (DCIS) after
breast conserving surgery deciding on (partial) breast radio-
therapy or no radiotherapy.
2) Patients with low risk invasive ductal carcinoma after breast
conserving surgery deciding on (partial) breast radiotherapy or
no radiotherapy.
3) Patients with intermediate risk breast cancer after mastectomy
deciding on thoracic wall radiotherapy or no radiotherapy.
4) Patients with intermediate risk breast cancer after breast
conserving surgery deciding on whole breast radiotherapy with
or without an additional boost dose to the tumor bed.2.1. Phase one: qualitative interviews
A qualitative study was conducted to explore the patients and
health care professionals (HPs) views on important attributes for
shared decision making for breast cancer patients deciding on
radiotherapy [30]. For this paper, we only report the data on the
communication of uncertainties. Data on other attributes and
preferences are published elsewhere [31].
2.2. Phase two: alpha testing the risk communication part of the
PtDA
With information derived from the interviews, the research
team developed a draft version of the risk communication part of
the PtDA. The PtDA was developed with input from both patients
and HPs in different rounds (Fig. 1).
2.2.1. Patient advocates recruitment
Patient advocates were recruited through the national breast
cancer association, the patient advisory group of the national breast
cancer research group and through the patient advisory board of
Maastro, one of the participating hospitals.
2.2.2. Health care professionals’ recruitment
Radiation oncologists, surgeons, radiotherapy physician assis-
tants and trial managers, all specialized in breast cancer, from 15
radiotherapy centers in the Netherlands were invited through
personal contacts.
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The draft version contained a PowerPoint presentation with a
schematic concept of the PtDA accompanied by a Word document
for patient advocates feedback. In round 1, the feedback was used to
make a first online PtDA version. In round 2, a live group meeting
with HPs and patent advocates was organized to discuss this online
version. The content and layout of the PtDA was discussed until
consensus was reached in the most important topics. In round 3,
thinking aloud sessions [32] were organized with new drafts of the
PtDA: Patient advocates reviewed the PtDAwhile speaking out loud
what they thought and understood. With this feedback a pre-finalFig. 1. Overview of the developmeversion was developed. Round 4 consisted of a second live group
meeting with HPs and patients. Here the pre-final version of the
PtDA was discussed until consensus was reached, on a version that
was created for testing in the field.3. Results
3.1. Phase one: qualitative interviews
Most patients and HPs agreed that recurrence risks, survival
data and side-effects in the PtDA should be communicated. Whilent of the Patient decision aid.
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risks, HPs also worried on how to communicate epistemic uncer-
tainty. While patients did not express a specific preference for risk
format, HPs agreed on communicating risks in a visual way. The
treatment burden was not mentioned as an important attribute to
decide on radiotherapy or not. The most relevant side-effects to
both patients and HPs were extracted from the interviews [31].
3.2. Phase two: alpha testing the risk communication part of the
PtDA
LRR and breast cancer specific survival (BCSS) were illustrated
by a pictograph, combined with textual explanation of the LRR/
BCSS: x out of 100 women will have a local recurrence in 10 years
(Fig. 2) and x out of 100 women will die from breast cancer in 10
years. No uncertainty was communicated.
Side-effects were divided in short term (red and sensitive skin,
edema, tiredness, and pain of the breast) and long-term side-effects
(fibrosis and change in breast shape, edema, (dark) skin dis-
colouration, pain, rib complications, heart problems and lung
problems). Due to lack of relevant data, no quantification on
probability could be given other than that side-effects could occur.
In round 1 patients understood the risks communicated on the
pictographs. The data on BCCS were experienced as confronting,
although patients thought that it was important to communicate.
The online version of the PtDA was developed together with an
e-learning company (EyeSpirations, Amersfoort, The Netherlands)
(Fig. 3).
During the live group meeting in round 2, with both patientsFig. 2. Pictograph in first draft version of the PtDA: Local recurrence risk for loand HPs there was agreement on the 10-year time frame for LRR.
For pathway 2 consensus was reached on point estimates. A debate
emerged on the LRR estimates of the other three pathways. It was
argued that no estimates could be given since the LRR depend on
individual patient, tumor and treatment characteristics but vali-
dated nomograms are lacking. The relative risk reduction is inde-
pendent of individual characteristics. Therefore, there was
consensus on mentioning both the absolute and the relative
reduction in recurrence risk in combination with a pictograph. The
absolute recurrence risk wasmentioned as a range in risk reduction
with an explanation that the patient’s clinician would personalise
the patient’s LRR. Two options were suggested for the pictographs.
The first option was to use fading colours in the 10  10 pictograph
to indicate a given risk with its uncertainty margin. The second
option was to show two different pictographs, one with the
smallest estimated recurrence risk, and another with the highest
estimated recurrence risk. Another debate emerged on how to
communicate survival risks. It was argued that BCSS is not prefer-
able the patient is mainly interested in overall survival expectancy.
Overall survival however, is impossible to generate for the whole
group since it also depends on patient characteristics, such as age,
and co-morbidity, In Pathway 1, 2 and 4 no gain in survival is ex-
pected from radiotherapy, therefore, it was decided to mention this
fact in words without putting an overall quantitative figure on it.
For the intermediate risk breast cancer after mastectomy (pathway
3) there is assumed to be a small in survival benefit (i.e. <2e3%),
which was described in this way in the PtDA.
Consensus on the information on the side-effects was reached
by adding only qualitative labels to indicate an estimation of thew risk breast cancer after breast conserving surgery without radiotherapy.
Fig. 3. Study-logo adapted pictographs with local recurrence risk with and without radiotherapy, in the first online version: Local recurrence risk for low risk breast cancer after
breast conserving surgery with and without radiotherapy.
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agreement that no estimates on frequency or severity of the ex-
pected side effects could be given, since there is a large variation in
experienced side effects between patients and there is no adequate
data available to predict this outcome for the individual pati€ent. For
the late side effects, distinction was made between common
(fibrosis and change in breast shape, edema and pain) and rare
side-effects ((dark) skin discolouration, rib complications, heart
problems and lung problems). Severity of the side-effects wasFig. 4. Pictograph without uncertainty range before round 3: 10 years local recurrence risk fo
with the BRASA logo pictographs replaced.qualified as varying between patients between almost no discom-
fort to very annoying. Smoking was added as an important risk
factor for heart problems and secondary lung cancer after breast
irradiation. Also, more information was added to the consequences
of the different side-effects.
For the thinking aloud sessions in round 3, new pictorial charts
were made. For pathway 2, pictographs with point estimates were
made (Fig. 4). For the other three pathways, there was a preference
for the pictographs with fading colours, ultimately a choice wasr low risk breast cancer after breast conserving surgery with and without radiotherapy,
D.B. Raphael et al. / The Breast 51 (2020) 105e113110made for orange and purple icons. The textual explanation was
placed on the virtual back of the pictographs. They were visualized
when patients clicked on the pictographs (Fig. 5a and b). It was
proposed to add more possible treatment options for the side-Fig. 5. a Turning pictograph with fading colours: 10 years Local recurrence risk intermed
pictograph with textual explanation on the back: 10 years Local recurrence risk intermediaeffects to the PtDA, such as physiotherapy.
In the second live meeting in round 4, the fading colouring
indicating the uncertainty margin of the female icons was found to
be unclear since the contrast was lost because of the fading scheme.iate risk breast cancer after mastectomy with and without radiotherapy.5b Turning
te risk breast cancer after mastectomy with and without radiotherapy.
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color of the icons step by step from orange to purple (Fig. 6), leading
to the final version of the pictograph for the PtDA.4. Discussion
In the development of a PtDA for breast cancer patients deciding
on adjuvant radiotherapy, we created a way to communicate
epistemic uncertainties when estimating LRR. Consensus was
reached between HPs and patients on a pictograph illustrating the
whole range of uncertainty, in combination with textual explana-
tion and information that their own physician would estimate a
more exact risk for the individual patient. The final pictograph
consisted of 100 female icons in a 10 x 10 array. The female icons
indicating the uncertainty margin of the LRRwere displayed as step
by step decolouring icons, from orange to purple (Fig. 6). The absent
or small gain in survival benefit of radiotherapy was communicated
by words without a quantitative number. Due to lack of reliable
evidence, the prevalence and severity of the possible side-effects
was only expressed in qualitative labels.
We used pictographs, they are known to improve patients un-
derstanding in risk communication [15,33e36]. Textual risk
communication is better understood in combination with visual
support [13]. The guideline on risk communication for PtDAs,
developed by the IPDAS collaboration, advises to use natural fre-
quencies and clear denominators over time and to be consistent,
using the same denominator in all examples [34]. The first online
version of the decision aid was therefore consistent with the known
literature.
In three of the four pathways, no consensus was reached on an
absolute value of a point-estimate for the LRR. Consequently, we
had to develop a way of communicating the epistemic uncertainty.
Although some effort has been put in researching how to
communicate aleatory uncertainty, less research has been done on
how to communicate epistemic uncertainty [22,23,34,37,38].Fig. 6. Pictograph with uncertainty margins, final version of PtDA: 10 years Local recur
radiotherapy.Communicating epistemic uncertainty may lead to more cancer
worries and may reduce trust, although available literature is
inconsistent to this point [37,39]. Communicating epistemic un-
certainty in a way that will not cause a negative impact therefore
seems important. We are not aware of other examples of PtDAs
communicating epistemic uncertainty in a visual way. In our study
consensus was reached on two-tone icons, showing the whole
width of epistemic uncertainty in combination with textual
explanation, and with the explanation that their own physician
would inform them further. Whether this is an effective method of
communicating epistemic uncertainty in a PtDA needs further
investigation in a clinical setting. At this moment, this way of
communicating epistemic uncertainty is being used in a pre-and
post-intervention study, the BRASA-study (clinical.trials.gov:
NCT03375801). In this study, we ask patients to fill out question-
naires to test their knowledge on their disease, to evaluate the
PtDA, and the process of shared decision-making.
As discussed earlier, qualitative risk labels are well understood
by patients but have the disadvantage of being interpreted in
different ways [15]. No clear data are available on the prevalence
and severity of side-effects of current radiotherapy for breast can-
cer patients. There is difference in the definition endpoint of side-
effects and different studies use different parameters to measure
the same outcome. For example to measure change in shape due to
fibrosis as a consequence of radiotherapy, cosmetic outcome has
been evaluated in several trials. Some studies use patient reported
outcome measures while others use scoring systems scored by
physicians or even computer systems evaluating photographs
[16,40]. Low agreement has been found between these different
methods [41,42]. Consequently, we could not include reliable esti-
mates for side-effects in the PtDA, not even using uncertainty
margins. Although we were aware of the shortcoming of commu-
nicating risks by qualitative labels, we felt we had no other option
and consensus was reached on using qualitative labels when
communicating both the frequency as well as the severity of therence risk for intermediate risk breast cancer after mastectomy with and without
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problem. With modern radiotherapy techniques radiotherapy dose
to the heart and lungs have been reduced, reducing long-term side
heart disease and lung cancer. For patients who smoke these risks
are substantially higher than for non-smokers [20]. Since in this
smoker-group the disadvantages might therefore outweigh the
advantages, this was mentioned separately.
Strengths and limitations: we were only able to include four
patient advocates in the development team who were mostly
highly educated. Patient advocates are trained patients [43] and
from literature we know that both patients and HPs involved in the
development of a PtDA have a learning curve. Patient advocates are
in a different situation, than patients looking at the PtDA for the
first time when making a decision on their treatment [44]. Despite
this shortcoming, the patient advocates took an active part in the
development team.
Conclusion: We incorporated pictographs with stepwise
gradient color icons indicating the uncertainty margin in combi-
nation with text, to communicate epistemic uncertainty in a PtDA
breast cancer patients deciding on radiotherapy. The prevalence
and severity of possible side-effects were communicated by qual-
itative labels. Currently the PtDA is being tested in a multi-center,
pre-and post-implementation study in the Netherlands, the
BRASA study.
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